Join to View Full Profile
2238 Geary BlvdSan Francisco, CA 94115
Phone+1 415-833-3692
Dr. Krackeler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Margaret Krackeler, MD, is an oncologist based in San Francisco, CA, specializing in hematologic oncology. She completed her internal medicine residency at University of California Davis Health from 2020 to 2023, followed by a fellowship in hematology and medical oncology at Kaiser Permanente Northern California (San Francisco) from 2023 to 2026. A graduate of Georgetown University School of Medicine's Class of 2020, Dr. Krackeler has contributed to several publications, including topics on prostate cancer, multidisciplinary discharge teams in leukemia therapy, Hyper-CVAD regimens in leukemia treatment, and a case report on T-cell LGL leukemia remission.
Education & Training
Kaiser Permanente Northern California (San Francisco)Fellowship, Hematology and Medical Oncology, 2023 - 2026
University of California Davis HealthResidency, Internal Medicine, 2020 - 2023
Georgetown University School of MedicineClass of 2020
Certifications & Licensure
CA State Medical License 2022 - 2026
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 4 citationsProstate cancer and bone: clinical presentation and molecular mechanisms.Kristina V Wells, Margaret L Krackeler, Maitreyee K Jathal, Mamta Parikh, Paramita M Ghosh
Endocrine-Related Cancer. 2023-09-01 - 1 citationsCharacterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute ...Vera Pervitsky, Julie Guglielmo, Benjamin Moskoff, Roxie Kneen, Carol Leija
Supportive Care in Cancer. 2023-03-21 - 3 citationsClinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehen...Tamer Othman, Benjamin N Moskoff, Gwendolyn Ho, Matthew E Tenold, Tali Azenkot
Leukemia Research. 2022-08-01
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
